Skip to main content
Premium Trial:

Request an Annual Quote

Dana Hosseini, Richard Durkee, Carl Feldbaum, George Jackowski, Rod Wilson, F. Mark Modzelewski, Patricia Dahia


Iceland Genomics has hired Sequenom alumnus Dana Hosseini to the positions of president and CEO, effective immediately. Hosseini also becomes a member of the board of directors.

Hosseini comes to Iceland Genomics from Sequenom, where he was director of business development, and from Cyntellect, where he was vice president of business development. He has also served in various international sales, marketing, and business-development roles in Abbott Laboratories, Iceland Genomics said.

Hosseini received an MBA and BS in biology from the University of British Columbia.

Applied DNA Sciences has appointed Richard Durkee to the company’s board of advisors.

Durkee, a network security consultant, will focus on integrating radio frequency identification and security systems design with Applied DNA Sciences’ wireless microchip and security access product applications.

Previously, Durkee was chief operating at Matrics, a developer of microelectronic devices for the RFID industry.

Carl Feldbaum said he will be retiring as president of the Biotechnology Industry Organization at the end of the year. Feldbaum has been with BIO for 11 years.

Feldbaum came to BIO from a stint as chief of staff to Senator Arlen Specter of Pennsylvania. He was also president and founder of the Palomar Corporation, a national security think tank headquartered in Washington, DC.

Feldbaum was also assistant to the Secretary of Energy, and served as the Inspector General for defense intelligence in the US Department of Defense. He received a bachelor’s degree in biology from Princeton University, and a law degree from the University of Pennsylvania Law School.

Feldbaum said he will remain as president emeritus “and to continue contributing to our industry as the new leadership deems appropriate.”

George Jackowski, CEO, CSO and chairman of Toronto-based SynX Pharma, and Rod Wilson, SynX's president and COO, are expected to join the management team of Nanogen pending the firm’s proposed acquisition of SynX.

F. Mark Modzelewski has joined the scientific advisory board of Acacia Research’s CombiMatrix group. He is the founder and executive director of the Nanobusiness Alliance.

Patricia Dahia, a researcher at Dana-Farber Cancer Institute, won the $10,000 Agencourt Pan-Mass Genomic Services Grant, Agencourt Bioscience said this week. Dahia, an instructor of medicine at the cancer center, received the grant for her proposal, “A Novel Familial Pheochromocytoma Susceptibility Locus: Toward Identification of the Target Gene.”

The goal of the project is to identify the gene or genes responsible for novel familial pheochromocytoma syndrome, a rare tumor of the adrenal gland that increases adrenaline production and dangerously elevates blood pressure, according to Agencourt.

The company noted that its high-throughput sequencing technologies will be used by Dahia to identify the susceptibility gene in the disorder.

Filed under

The Scan

Guidelines for Ancient DNA Work

More than two dozen researchers have developed new ethical guidelines for conducting ancient DNA research, which they present in Nature.

And Cleared

A UK regulator has cleared former UK Prime Minister David Cameron in concerns he should have registered as a consultant-lobbyist for his work with Illumina, according to the Financial Times.

Suit Over Allegations

The Boston Globe reports that David Sabatini, who was placed on leave from MIT after allegations of sexual harassment, is suing his accuser, the Whitehead Institute, and the institute's director.

Nature Papers on Esophageal Cancer, Origin of Modern Horses, Exome Sequencing of UK Biobank Participants

In Nature this week: genetic and environmental influences of esophageal cancer, domestic horse origin traced to Western Eurasian steppes, and more.